Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0000875320-25-000057 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | 2025-02-12 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +2,080 | 12.0K | +21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | A | A | 2,080 | $0.00 | 12,033 | D | — | — | (F1) Restricted stock unit award that vests in installments beginning on 02/24/2026. |